Review article: Helicobacter pylori and gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 1, 2005, Pages 32-40

  Delaney, B ^a   McColl, K ^b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c Section of Surgery   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

AGING; CANCER RISK; CLINICAL TRIAL; DRUG EFFECT; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; NONULCER DYSPEPSIA; PRIORITY JOURNAL; REBOUND; REVIEW; STOMACH ACID SECRETION; STOMACH CANCER;

EID: 23844522542     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02607.x     Document Type: Review

References (68)

1. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326: 737.
2. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004; 99: 1652-6.
3. Warburton-Timms V, Charlett A, Valori RM, et al. The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 341-6.
4. Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-oesophageal reflux disease in Chinese. World J Gastroenterol 2004; 10: 672-5.
5. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 387-96.
6. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-13.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med 1999; 340: 825-31.
8. Parsonnet J, Forman D. Helicobacter pylori infection and gastric cancer - for want of more outcomes. JAMA 2004; 291: 244-5.
9. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.
10. Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733-44.
11. Moayyedi P, Deeks J, Talley NJ, Delaney BC, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic review. Am J Gastroenterol 2003; 98: 2621-6.
12. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian Audit Dyspepsia Empiric Treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002; 324: 1012-6.
13. Moayyedi P, Feltbower R, Brown J, et al. The effect of population H. pylori screening and treatment on dyspepsia and quality of life in the community: results of a randomised controlled trial. Lancet 2000; 355: 1665-9.
14. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication of heartburn and gastrooesophageal reflux: Bristol Helicobacter Project. BMJ 2004; 328: 1417-9.
15. Wildner-Christensen M, Hansen JM, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003; 125: 372-9.
16. Vaira D, Vakil N, Rugge M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 2003; 52: 1543-7.
17. Moayyedi P, Delaney B, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329-37.
18. McColl KEL, El-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998; 54: 121-38.
19. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med 2001; 345: 784-9.
20. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
21. Smith JTL, Pounder RE, Nwokolo CU, et al. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522-5.
22. Katelaris PH, Seow F, Lin BPC, Napoli J, Ngu MC, Jones DB. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993; 34: 1032-7.
23. Peterson WL, Barnett CC, Doyle BS, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88: 2038-43.
24. Grossman MI, Kirsner JB, Gillespie IE. Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 1963; 45: 14-26.
25. Hitchcock CR, Sullivan WA, Wangensteen OH. The value of achlorhydria as a screening test for gastric cancer. Gastroenterology 1955; 29: 621-32.
26. Comfort MW, Kelsey MP, Berkson J. Gastric acidity before and after the development of carcinoma of the stomach. J Natl Cancer Inst 1947; 7: 367-73.
27. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med 1951; 34: 1331-47.
28. El-Omar EM, Carrington M, Wong-Ho C, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-9.
29. Naylor GM, Gotada T, Gatta L, et al. A comparison of gastritis between a UK and a Japanese population. Gut 2004; 53 (Suppl. 3): A22.
30. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
31. Yamaji Y, Mitsushima T, Ikuma H, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut 2001; 49: 335-40.
32. Abe Y, Ohara S, Koike T, et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol 2004; 99: 1213-21.
33. Takeuchi Y, Kimura J. The result of post-marketing surveillance of omeprazole (Omepral® and Omeprazon®). J Cancer 1990; 62: 440-3.
34. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
35. Blot W, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma at the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
36. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-3.
37. 7 Botterweck AAM, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645-54.
38. Wijnhoven BPL, Louwan MWJ, Tilanus HW, Coebergh J-WW. Increased incidence of adenocarcinoma at the gastrooesophageal junction in Dutch males since the 1990s. Eur J Gastroenterol Hepatol 2002; 14: 115-22.
39. Hansson LE, Sparen P, Nyren O. Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985. Br J Surg 1993; 80: 374-7.
40. Wu YCY, Chan FKL, Wong SKH, Lee YT, Leung W, Sung JJY. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 2002; 16: 545-52.
41. Koike T, Ohara S, Sekine H, et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 813-20.
42. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
43. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 1738-42.
44. Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13: 915-20.
45. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon ATR. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
46. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 914-20.
47. Malfertheiner P, Ossner J, Fischbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 615-25.
48. Feldman M, Cryer B, Sammer D, Lee E, Spechler SJ. Influence of H. pylori infection meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277: G1159-64.
49. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
50. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-6.
51. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
52. Verdu EF, Armstron D, Idstrom J-P, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1151-6.
53. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-81.
54. Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
55. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long term safety. Am J Gastroenterology 1995; 90: 1401-6.
56. Sachs G. Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 1997; 112: 487-95.
57. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
58. Wu JCY, Chan FKL, Ching JYL, et al. Effect of Helicobacter pylori on treatment of gastro-oesophageal reflux disease: a double-blind, placebo-controlled, randomised trial. Gut 2004; 53: 174-9.
59. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20.
60. Gillen D, McColl KEL. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15: 487-95.
61. Gillen D, McColl KEL. Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol 2001; 89: 281-6.
62. Kuipers EJ, Lundell L, Klinkenberg EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. New Engl J Med 1996; 334: 1018-22.
63. Lundell L, Miettinen P, Myrvold HE and the Nordic GORD Study Group. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319-26.
64. Pounder RE, Williams MP. Omeprazole and the accelerated onset of atrophic gastritis. Gastroenterology 2000; 118: 238-43.
65. Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000; 14: 1345-52.
66. Geboes K, Dekker W, Mulder CJJ on Behalf of the Dutch Study Group. Long-term lansoprazole treatment for gastrooesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 18: 1819-26.
67. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53.
68. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6: 789-92.